Know How Sparse Data AI Augments Pharmaceutical Processes
The implementation of sparse data AI bolsters the experimental results and provides accurate predictions regarding the behavior of molecules under specific conditions.
FREMONT, CA – The transition toward value-based healthcare has spurred the pharmaceutical industry to leverage emerging technologies such as artificial intelligence (AI) to improve predictive models in drug discovery and development. The big data fueled by the troves of information generated in R&D has facilitated valuable insights, leading to innovative healthcare approaches.
However, the introduction of sparse data AI has paved novel pathways for drug discovery and development. It has enabled the companies to form sophisticated biochemistry models backed by comprehensive explanation and inference. The incorporation of Artificial Intelligence has promoted higher transparency as well as productivity in the pharma industry.
In the pharmaceutical world, computational chemistry is used to predict convolute organic reactions and their outcomes. However, the conventional approaches to prediction are expensive as well as time-consuming. The new models are designed to create useful reaction sequences for selected target molecules. However, it is yet to be seen whether the models can form predictions outside the training data.
Organizations leverage big data to form flexible predictive models utilizing minimal domain knowledge. To predict the physiochemical properties of drug molecules, deep learning is often incorporated into big data. However, the last few years have witnessed a dramatic increase in the amount of available data due to the introduction of high-throughput screening and synthesis. Hence, it has become inevitable to incorporate AI to access vast datasets.
Bayesian Sparse Data Optimization
The applications of big data are limited since it utilizes algorithms without comprehending the underlying mechanisms involved in the model. The implementation of sparse data AI, on the other hand, can understand the references and offer better outcomes. It bolsters the experimental results with expert knowledge on the mechanism and provides accurate predictions regarding the behavior of molecules under specific conditions.
Incorporating Bayesian optimization to the sparse data AI enables the development of a sequential model-based approach. The process can be used to identify the optimal model, even with the presence of multiple unknowns. Sparse data AI has provided the pharmaceutical industry with the necessary tools to analyze vast troves of information and draw valuable insights. Hence, it is imperative for organizations to employ robust approaches in the different stages of drug discovery and development. It will not only introduce greater efficiency and productivity in the sector but will also help the patients to receive enhanced healthcare.
Check This Out: Top Pharmaceutical Compliance Consulting Companies
CIO Review Client: Flagship
By Leni Kaufman, VP & CIO, Newport News Shipbuilding
By George Evans, CIO, Singing River Health System
By John Kamin, EVP and CIO, Old National Bancorp
By Elliot Garbus, VP-IoT Solutions Group & GM-Automotive...
By Gregory Morrison, SVP & CIO, Cox Enterprises
By Alberto Ruocco, CIO, American Electric Power
By Sam Lamonica, CIO & VP Information Systems, Rosendin...
By Sergey Cherkasov, CIO, PhosAgro
By Pascal Becotte, MD-Global Supply Chain Practice for the...
By Stephen Caulfield, Executive Director, Global Field...
By Shamim Mohammad, SVP & CIO, CarMax
By Ronald Seymore, Managing Director, Enterprise Performance...
By Brad Bodell, SVP and CIO, CNO Financial Group, Inc.
By Jim Whitehurst, CEO, Red Hat
By Clark Golestani, EVP and CIO, Merck
By Scott Craig, Vice President of Product Marketing, Lexmark...
By Dave Kipe, SVP, Global Operations, Scholastic Inc.
By Meerah Rajavel, CIO, Forcepoint
By Amit Bahree, Executive, Global Technology and Innovation,...
By Greg Tacchetti, CIO, State Auto Insurance